Latest News

New data for daclizumab in MS

 

Daclizumab is an IgG1 anti-CD25 monoclonal antibody that blocks IL-2-mediated lymphocyte activation. The drug (Zenapax) was originally used to prevent tissue rejection but was withdrawn by Roche in 2009 due to declining demand.      Read More

TOPICS:

Environmental factors in MS: Air and vitamin D

 

REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Few studies have examined the potential impact of ambient air quality and airborne particulates on multiple sclerosis. A decade ago, a study in Finland suggested that the frequency of MS relapses was higher with increasing levels of inhaled particulates (Oikonen et al. Neuroepidemiology 2003;22:95-99). Read More

TOPICS:

Gut microbiome and MS pathogenesis

 

REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Several lines of evidence indicate that the gut microbiome plays a role in the pathogenesis of MS. It has been suggested that environmental risk factors, such as diet, vitamin D insufficiency, obesity and smoking, may contribute to alterations in the GI flora that may predispose to autoimmune dysregulation (Joscelyn & Kasper. Mult Scler 2014; epublished July 28, 2014).

Gut flora, such as Bacteroides fragilis, produce short-chain fatty acids which have been shown in animal models to have anti-inflammatory effects on peripheral immune cells and which are involved in the proliferation of regulatory T cells (Tregs) (Smith et al. Science 2013;341:569-573; Maslowski et al. Nature 2009;461:1282-1286; Furusawa et al. Nature 2013;504:446-450). Read More

TOPICS: